{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:23:12Z","timestamp":1789471392945,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shandong Yeedo Biotechnology Co., Ltd. (Dongying, Shandong, China)","award":["201719704-C"],"award-info":[{"award-number":["201719704-C"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Objectives: This study evaluated the 12-month persistence of rabies virus-neutralizing antibody (RVNA) following different immunization regimens of freeze-dried human rabies vaccine (Vero cells) in individuals aged 10\u201360 years within the Chinese population. Methods: Number of 600 participants from phase III clinical trials who completed the fullimmunization were randomly assigned into one of three groups, four-dose experimental group, five-dose experimental group, and five-dose control group. The experimental group received the vaccine from Shandong Yeedu Biotechnology Co., while the control group used the vaccine from Liaoning Chengda Biotechnology Co., Ltd. The antibody-positive rate and geometric mean concentration (GMC) were calculated, and analysis of variance was used to compare the results among the three groups. Results: The study included 200 participants in the four-dose experimental group, 186 in the five-dose experimental group, and 214 in the five-dose control group. Twelve months post-immunization, the overall RVNA-positive rates were 97.00%, 93.55%, and 94.86% in the four-dose experimental, five-dose control, and five-dose experimental groups, respectively. The GMCs of RVNA were 2.50, 2.05, and 2.04 IU\/mL for the respective groups. The age-stratified analysis exhibited high positivity rates across age groups (\u226421, 21\u201350, and \u226550), with rates ranging from 88.4% to 100%, and GMCs were between 1.75 and 2.61 IU\/mL. Conclusions: Twelve months after full immunization, the overall RVNA-positive rate remained high across all dosing regimens, demonstrating satisfactory immunogenicity persistence. This indicates that both the four-dose and five-dose regimens are effective in maintaining long-term immunity against rabies.<\/jats:p>","DOI":"10.3390\/vaccines12111209","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T03:46:04Z","timestamp":1729827964000},"page":"1209","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10\u201360 Years Age Group: A Follow-Up Report Based on Phase III Clinical Trial"],"prefix":"10.3390","volume":"12","author":[{"given":"Yunpeng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Biologicals Testings, National Institute for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Shandong Yeedo Biotechnology Co., Ltd., Dongying 257091, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-5439","authenticated-orcid":false,"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biologicals Testings, National Institute for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouchun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Biologicals Testings, National Institute for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-8855","authenticated-orcid":false,"given":"Leitai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Biologicals Testings, National Institute for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biologicals Testings, National Institute for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Mo","sequence":"additional","affiliation":[{"name":"Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liang","sequence":"additional","affiliation":[{"name":"Shandong Yeedo Biotechnology Co., Ltd., Dongying 257091, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6471-1285","authenticated-orcid":false,"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biologicals Testings, National Institute for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/21645515.2020.1778408","article-title":"Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: A randomized, double-blind, positive controlled phase 3 clinical trial","volume":"17","author":"Shen","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/21645515.2017.1279770","article-title":"Immunogenicity, Safety and Antibody Persistence of a Purified Vero Cell Cultured Rabies Vaccine (Speeda) Administered by the Zagreb Regimen or Essen Regimen in Post-Exposure Subjects","volume":"13","author":"Shi","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_3","unstructured":"World Health Organization (2024, July 24). WHO Expert Consultation on Rabies. Second Report. Technical Report Series No. 931. Available online: https:\/\/www.who.int\/publications\/i\/item\/who-trs-931."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0264-410X(88)90225-3","article-title":"Interaction of Rabies Vaccine with Human Rabies Immunoglobulin and Reliability of a 2-1-1 Schedule Application for Postexposure Treatment","volume":"6","author":"Vodopija","year":"1988","journal-title":"Vaccine"},{"key":"ref_5","first-page":"1","article-title":"Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices","volume":"59","author":"Rupprecht","year":"2010","journal-title":"MMWR Recomm. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"World Health Organization (2010). Rabies vaccines: WHO position paper\u2013recommendations. Vaccine, 28, 7140\u20137142.","DOI":"10.1016\/j.vaccine.2010.08.082"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.4161\/21645515.2014.972773","article-title":"A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults","volume":"10","author":"Ma","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/21645515.2014.995059","article-title":"Comparative Study on the Immunogenicity and Safety of a Purified Chick Embryo Cell Rabies Vaccine (PCECV) Administered According to Two Different Simulated Post Exposure Intramuscular Regimens (Zagreb versus Essen)","volume":"11","author":"Mahendra","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2211896","DOI":"10.1080\/21645515.2023.2211896","article-title":"Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10-50 years old: Randomized, blinded, parallel controlled phase III clinical study","volume":"19","author":"Huang","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.vaccine.2022.06.035","article-title":"Safety and Immunogenicity of Human Rabies Vaccine for the Chinese Population After PEP: A Systematic Review and Meta-Analysis","volume":"40","author":"Wang","year":"2022","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1080\/21645515.2021.1880200","article-title":"Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/21645515.2016.1230260","article-title":"Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above","volume":"13","author":"Wang","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.vaccine.2011.01.053","article-title":"Safety and Immunogenicity of Two Freeze-Dried Vero Cell Rabies Vaccines for Human Use in Post-Exposure Prophylaxis","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"ref_14","unstructured":"Center For Drug Evaluation, China (2024, July 12). Guidelines for Clinical Research on Human Rabies Vaccines. Available online: https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/c670820fd316d8977dc72c4fa7aaa749."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/j.ijid.2009.08.008","article-title":"Serologic Response to Rabies Pre-Exposure Vaccination in Persons with Potential Occupational Exposure in Singapore","volume":"14","author":"Lim","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_16","first-page":"taw011","article-title":"One-Year Immunogenicity Kinetics and Safety of a Purified Chick Embryo Cell Rabies Vaccine and an Inactivated Vero Cell-Derived Japanese Encephalitis Vaccine Administered Concomitantly According to a New, 1-Week, Accelerated Primary Series","volume":"23","author":"Cramer","year":"2016","journal-title":"J. Travel Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Overduin, L.A., van Dongen, J.J.M., and Visser, L.G. (2019). The Cellular Immune Response to Rabies Vaccination: A Systematic Review. Vaccines, 7.","DOI":"10.3390\/vaccines7030110"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1128\/CVI.05090-11","article-title":"Persistence of Rabies Antibody 5 Years After Postexposure Prophylaxis with Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose","volume":"18","author":"Zhang","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_19","unstructured":"National People\u2019s Congress of P.R.C. (2024, July 12). The China Vaccine Administration Law, Available online: http:\/\/www.npc.gov.cn\/npc\/c30834\/201907\/11447c85e05840b9b12c62b5b645fe9d.shtml."},{"key":"ref_20","first-page":"44","article-title":"Comparison of Compliance and Economic Cost of Two Different Immunization Procedures for Rabies Vaccine","volume":"26","author":"Yan","year":"2020","journal-title":"Contemp. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/11\/1209\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:20:01Z","timestamp":1760113201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/11\/1209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["vaccines12111209"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12111209","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}